FI20050941A - A method for selecting a therapeutically effective agent that binds to alpha4beta1 or a ligand thereof for use in suppressing an immune response - Google Patents
A method for selecting a therapeutically effective agent that binds to alpha4beta1 or a ligand thereof for use in suppressing an immune response Download PDFInfo
- Publication number
- FI20050941A FI20050941A FI20050941A FI20050941A FI20050941A FI 20050941 A FI20050941 A FI 20050941A FI 20050941 A FI20050941 A FI 20050941A FI 20050941 A FI20050941 A FI 20050941A FI 20050941 A FI20050941 A FI 20050941A
- Authority
- FI
- Finland
- Prior art keywords
- present
- receptor
- beta
- alpha
- ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 4
- 230000001684 chronic effect Effects 0.000 abstract 2
- 108010036236 extracellular matrix receptor Proteins 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000001994 activation Methods 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000006472 autoimmune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand. The invention is based upon the discovery that the alpha 4 beta 1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the alpha 4 beta 1 receptor had not been identified, nor had the function of the alpha 4 beta 1 receptor in lymphocyte attachment been known. By preventing the interaction between the alpha 4 beta 1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues. The present invention, therefore, has particular clinical utility in suppression of the immune response, in various specific embodiments of the invention, the adherence of lymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localized to particular tissues or circumscribed areas. Accordingly, the present invention provides for treatment of diseases involving autoimmune responses as well as other chronic or relapsing activations of the immune system, including allergy, asthma, and chronic inflammatory skin conditions.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40238989A | 1989-09-01 | 1989-09-01 | |
| US40238989 | 1989-09-01 | ||
| PCT/US1990/004978 WO1991003252A1 (en) | 1989-09-01 | 1990-08-31 | Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction |
| US9004978 | 1990-08-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI20050941A true FI20050941A (en) | 2005-09-21 |
| FI118842B FI118842B (en) | 2008-04-15 |
Family
ID=23591680
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI920899A FI116793B (en) | 1989-09-01 | 1992-02-28 | A method of selecting a therapeutically effective antibody, fragment or derivative thereof, or peptide that binds to alpha4beta1 |
| FI20050941A FI118842B (en) | 1989-09-01 | 2005-09-21 | A method for selecting a therapeutically active substance that binds to alpha4beta1, or its ligand, for use in inhibiting lymphocyte migration via vascular endothelial cell layers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI920899A FI116793B (en) | 1989-09-01 | 1992-02-28 | A method of selecting a therapeutically effective antibody, fragment or derivative thereof, or peptide that binds to alpha4beta1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP0489837B2 (en) |
| JP (1) | JP3357359B2 (en) |
| KR (1) | KR100188459B1 (en) |
| AT (1) | ATE253642T1 (en) |
| AU (1) | AU654657B2 (en) |
| CA (1) | CA2065292C (en) |
| DD (1) | DD297562A5 (en) |
| DE (3) | DE122006000044I1 (en) |
| DK (1) | DK0489837T4 (en) |
| ES (1) | ES2210225T5 (en) |
| FI (2) | FI116793B (en) |
| GR (2) | GR1001372B (en) |
| IE (2) | IE903169A1 (en) |
| IL (3) | IL95501A (en) |
| LU (1) | LU91273I2 (en) |
| NL (1) | NL300240I2 (en) |
| NZ (1) | NZ235131A (en) |
| PT (1) | PT95180A (en) |
| WO (1) | WO1991003252A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5730978A (en) * | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US7238668B1 (en) | 1989-09-01 | 2007-07-03 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof |
| US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
| US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
| WO1993012809A1 (en) * | 1991-12-24 | 1993-07-08 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
| DK0626861T4 (en) | 1992-01-13 | 2004-08-16 | Biogen Inc | Treatment of asthma. |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| IL102646A (en) * | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
| EP0670735B1 (en) | 1992-11-13 | 1997-04-02 | Board Of Regents Of The University Of Washington | Peripheralization of hematopoietic stem cells |
| AU687790B2 (en) † | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| DE69412470T3 (en) † | 1993-03-18 | 2006-07-20 | Naamloze Vennootschap Innogenetics S.A. | METHOD FOR HLA-B TYPING BY MEANS OF SPECIFIC PRIMERS AND SAMPLE SETS |
| ZA947006B (en) * | 1993-09-15 | 1995-05-02 | Univ Emory | Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions |
| US5936065A (en) * | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5821231A (en) * | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
| WO1995015973A1 (en) * | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| CN1211123C (en) * | 1994-01-25 | 2005-07-20 | 雅典娜神经科学公司 | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| FR2724393A1 (en) * | 1994-09-12 | 1996-03-15 | Inst Nat Sante Rech Med | OBTAINING A HUMANIZED RECOMBINANT MONOCLONAL ANTIBODY FROM A MURIN MONOCLONAL ANTIBODY, ITS PRODUCTION IN INSECT CELLS, AND USES THEREOF |
| WO1997035557A1 (en) * | 1996-03-22 | 1997-10-02 | Kao Corporation | External skin-care composition |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| IL163725A0 (en) | 2002-02-25 | 2005-12-18 | Elan Pharm Inc | Administration of agents for the treatment of inflammation |
| US7125650B2 (en) | 2004-07-20 | 2006-10-24 | Roberts David H | Method for bump exposing relief image printing plates |
| TWI723339B (en) | 2011-05-02 | 2021-04-01 | 美商千禧製藥公司 | Formulation for anti-α4β7 antibody |
| UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
| WO1990008833A1 (en) * | 1989-02-02 | 1990-08-09 | Massachusetts Institute Of Technology | Expression of recombinant fibronectin in genetically engineered cells |
-
1990
- 1990-08-27 IL IL95501A patent/IL95501A/en active IP Right Grant
- 1990-08-27 IL IL11326190A patent/IL113261A/en active IP Right Grant
- 1990-08-28 GR GR930100041A patent/GR1001372B/en not_active IP Right Cessation
- 1990-08-28 GR GR900100648A patent/GR1001161B/en not_active IP Right Cessation
- 1990-08-31 WO PCT/US1990/004978 patent/WO1991003252A1/en active IP Right Grant
- 1990-08-31 DE DE1990634116 patent/DE122006000044I1/en active Pending
- 1990-08-31 AT AT90913598T patent/ATE253642T1/en active
- 1990-08-31 EP EP90913598.0A patent/EP0489837B2/en not_active Expired - Lifetime
- 1990-08-31 CA CA002065292A patent/CA2065292C/en not_active Expired - Lifetime
- 1990-08-31 DE DE69034116.4T patent/DE69034116T3/en not_active Expired - Lifetime
- 1990-08-31 ES ES90913598.0T patent/ES2210225T5/en not_active Expired - Lifetime
- 1990-08-31 IE IE316990A patent/IE903169A1/en active IP Right Review Request
- 1990-08-31 KR KR1019920700621A patent/KR100188459B1/en not_active IP Right Cessation
- 1990-08-31 DK DK90913598.0T patent/DK0489837T4/en active
- 1990-08-31 NZ NZ235131A patent/NZ235131A/en unknown
- 1990-08-31 PT PT95180A patent/PT95180A/en not_active Application Discontinuation
- 1990-08-31 AU AU63542/90A patent/AU654657B2/en not_active Expired
- 1990-08-31 IE IE20040028A patent/IE20040028A1/en not_active IP Right Cessation
- 1990-08-31 EP EP20030017578 patent/EP1366769A1/en not_active Withdrawn
- 1990-08-31 DE DE122006000044C patent/DE122006000044I2/en active Active
- 1990-08-31 JP JP51276390A patent/JP3357359B2/en not_active Expired - Lifetime
- 1990-09-03 DD DD90343788A patent/DD297562A5/en unknown
-
1992
- 1992-02-28 FI FI920899A patent/FI116793B/en active IP Right Grant
-
1995
- 1995-04-05 IL IL11326195A patent/IL113261A0/en unknown
-
2005
- 2005-09-21 FI FI20050941A patent/FI118842B/en active IP Right Grant
-
2006
- 2006-08-10 LU LU91273C patent/LU91273I2/en unknown
- 2006-08-11 NL NL300240C patent/NL300240I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI20050941A (en) | A method for selecting a therapeutically effective agent that binds to alpha4beta1 or a ligand thereof for use in suppressing an immune response | |
| Henocq et al. | Skin eosinophilia in atopic patients | |
| Maizel et al. | Long-term growth of human B cells and their use in a microassay for B-cell growth factor. | |
| KR950700333A (en) | IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR ITS PRODUCTION FROM HUMAN PERIPHERAL BLOOD LEUKOCYTES | |
| Sahni et al. | Interleukin-1β but not IL-1α binds to fibrinogen and fibrin and has enhanced activity in the bound form | |
| DE69736184D1 (en) | Antagonists of G protein-coupled receptors | |
| WO1998018826A3 (en) | Anti-CCR5 antibodies and methods of use therefor | |
| CA2118309A1 (en) | Lymphocyte Activation Antigen HB15, a Member of the Immunoglobulin Superfamily | |
| Takii et al. | Interleukin‐1 up‐regulates transcription of its own receptor in a human fibroblast cell line TIG‐1: role of endogenous PGE2 and cAMP | |
| Schneider et al. | Isolation of a biologically active macrophage receptor for the third component of complement | |
| Fabris et al. | Fibrogenesis serum markers in patients with chronic hepatitis C treated with α-IFN | |
| FI883351A0 (en) | DIAGNOSTIC METHOD FOR THE POVERTY OF RNA-AS RNA-AS L. | |
| Li et al. | Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro | |
| Baughman et al. | Systemic immune response of patients with active pulmonary sarcoidosis. | |
| Simpson et al. | Soluble adhesion molecules in immune mediated liver disease. | |
| Cavender et al. | Inhibition by IL-1 of endothelial cell activation induced by tumor necrosis factor or lymphotoxin. | |
| DE3485787D1 (en) | METHOD AND STROMATOLYSIS AGENT FOR THE VOLUMETRIC DETERMINATION OF LEUCOCYTE POPULATIONS. | |
| Singh et al. | Purification and biochemical properties of a human monocyte-derived growth factor. | |
| Finbloom et al. | The receptor for interferon-gamma on human peripheral blood monocytes consists of multiple distinct subunits. | |
| Miyasato et al. | Eosinophil chemiluminescence response to cytokines and opsonized zymosans in atopic dermatitis | |
| Fine et al. | Evaluation of chemokine-and phlogistin-mediated leukocyte chemotaxis using an in vivo sponge model | |
| Lowe et al. | T lymphocyte participation in acute serum sickness glomerulonephritis in rabbits | |
| IT9020113A0 (en) | USE OF SP-2 MONOCLONAL ANTIBODY IN CLINICAL DIAGNOSIS AND MONITORING THE PROGRESS OF HIV INFECTION | |
| DE790059T1 (en) | DEVICE FOR TREATING AUTO-IMMUNE DISEASES AND METHOD FOR TREATING | |
| He et al. | 366 Injection of histamine with mast cell tryptase selectively stimulates eosinophil accumulation In vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118842 Country of ref document: FI |